3292.8000 34.00 (1.04%)
NSE Jun 26, 2025 15:30 PM
Volume: 156.4K
 

3292.80
1.04%
Motilal Oswal
Revenue grew 22% YoY to INR7.9b (est. INR8.1b), led by Dermatology, AntiInfectives, and Pain/Analgesics segment. Gross margin expanded by 40bp YoY to 61.7% due to better product mix. EBITDA margin expanded at a higher rate (160bp YoY) to 19% (est. 21.5%) due to better operating leverage, with lower employee cost (down 220bp YoY as a percentage of sales), partially offset by higher other opex (+100bp...
Number of FII/FPI investors decreased from 347 to 340 in Mar 2025 qtr
More from GlaxoSmithKline Pharmaceuticals Ltd.
Recommended